# Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction

> **NCT06742567** · PHASE3 · RECRUITING · sponsor: **National Institute of Cardiovascular Diseases, Pakistan** · enrollment: 472 (estimated)

## Conditions studied

- Acute Myocardial Infarction of Anterior Wall
- Left Ventricular Thrombus
- Prophylaxis

## Interventions

- **DRUG:** Apixaban 2.5 MG PO BID
- **DRUG:** Control (Standard treatment)

## Key facts

- **NCT ID:** NCT06742567
- **Lead sponsor:** National Institute of Cardiovascular Diseases, Pakistan
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-02
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 472 (ESTIMATED)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06742567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06742567, "Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06742567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*